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 The cell wall is a common component found in nearly 
all bacteria. Long validated as a drug target for over 
half of all prescribed antibiotics, it continues to offer 
new sources for increasing that number ever further. 
Eschewing the ubiquitous transpeptidase-targeting beta 
lactams, pathways for the biosynthesis of the rhamnose 
linker between peptidoglycan and arabinogalactan, and 
peptidoglycan itself, provide alternatives for developing 
novel antibiotics to pathogenic bacteria. 
 The first half of this study will focus on the four-
member pathway responsible for the production of dTDP-L-
rhamnose and includes a structural analysis of some 
members found in Mycobacterium tuberculosis (Mtb) in 
conjunction with their respective inhibitors. The specific 
architecture of each individual inhibitor inside the 
active site of the enzyme offers insight into the role 
each atom plays in binding and explains why small 
variations of the compound influence this relationship. 
This same variation also affects the ability of the 




 The second half of this study will focus on the first 
step of the pathway for biosynthesis of uridine 
diphosphate N-acetylmuramic acid pentapeptide, the 
immediate precursor to peptidoglycan. UDP-N-
acetylglucosamine enolpyruvyl transferase (MurA) catalyzes 
the transfer of the enolpyruvyl moiety of 
phosphoenolpyruvate to the 3’ hydroxyl group of UDP-N-
acetylglucosamine, yielding enolpyruvyl-UDP-N-
acetylglucosamine and phosphate. This enzyme is highly 
conserved among bacteria and found as a single copy in 
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INTRODUCTION AND LITERATURE OVERVIEW 
 
 The ability of pathogenic bacteria to elude 
antibiotics presents an ever present and increasing threat 
to the worldwide human health. Various forms of 
evolutionary adaptations have rendered some antibiotics 
virtually ineffective. Research continues onward to 
improve validated classes of antibiotics, in conjunction 
with creating new ones. The differential nature of the 
bacteria cell wall relative to eukaryotic cells has made 
it a vast and extensively probed target and will continue 












 Rhamnose is found in nature in both the L- and D-
forms. While no usage or dietary requirement has been 
discovered in humans, rhamnose can be found in bacteria, 
archaea, plants, fungi, and even viruses[3-8]. The 
biosynthetic process is similar across organisms, 
beginning with glucose. The enzymes differ in their exact 
mechanism, including bifunctional enzymes, but the basic 
four steps, transferase, dehydratase, epimerase, and 
reductase, are maintained. The final form of rhamnose, 
dTDP-L-rhamnose, UDP-L-rhamnose, GDP-D-rhamnose, GMP-D-
rhamnose, depends on the specific usage, which depends on 
the organism. Pseudomonas aeruginosa utilizes both the L- 
and D-forms, for rhamnolipids and lipopolysaccharides, 
respectively[7]. The archaeon Thermoplasma acidophilum 
metabolizes L-rhamnose as its sole carbon source[9]. A 
small number of viruses, such as Acanthocystis turfacea 
chlorella virus 1 and Acanthamoeba polyphaga mimivirus, 
utilize UDP-L-rhamnose for posttranslational modification 
of their capsid proteins[6]. Arabidopsis thaliana requires 
UDP-L-rhamnose for the biosynthesis of the pectic 
polysaccharide rhamnogalacturonan-I, needed for proper 




In most bacteria, rhamnose is not required for 
survival. A lack of rhamnose may affect overall fitness or 
the ability to sustain a pathogenic infection but may not 
constitute an absolute requirement[8]. The position or 
levels of rhamnose determine whether the rml genes are 
essential. For instance, Pseudomonas aeruginosa can 
survive without rhamnose but its ability to infect is 
severely compromised[11]. However, in some bacteria such 
as the human pathogen Streptococcus pyogenes, roughly half 
of the cell wall is comprised of a rhamnose-rich 
polysaccharide[12]. Mycobacterium tuberculosis, and all 
Mycobacterium species studied to date, employ dTDP-L-
rhamnose to incorporate a rhamnosyl linker into the cell 
wall, connecting the peptidoglycan layer to the 
arabinogalactan layer[13]. In both of these cases, 
rhamnose is absolutely essential for survival. The 
specific and singular use in Mycobacterium tuberculosis 
has led to the rhamnose pathway being considered a 
candidate for a novel antibiotic. The first section of 
this record of study evaluates the biochemical and 
structural nature of the enzymes of the pathway, in 
conjunction with evaluations of inhibitors and analogs to 




 Rhamnose is used for wide variety of purposes in 
plants, from structural to seed coatings, and even the 
color of flowers reflected in rhamnosylated anthocyanins 
found within the petals[4, 10, 14]. The pathway is similar 
to that found in bacteria, in that a diphosphonucleotide-
charged rhamnose (NDP-rhamnose) is produced. However, most 
plants, such as Arabidopsis thaliana, combine the last two 
steps within a single bifunctional enzyme roughly twice 
the size of the bacterial homologues comprising RmlC and 
RmlD[4]. This bifunctional enzyme is expressed as a 
polypeptide which also includes the RmlB dehydratase 
activity in the N-terminal region. Sequence alignments 
offer additional evidence. The N-terminal region of RHM2 
strongly aligns with bacterial examples of RmlB[15]. The 
C-terminal region strongly aligns with bacterial RmlD’s 
but also include canonical sequences found in the 
catalytic region of epimerases. The entire polypeptide 
exists as three isoforms: RHM1, RHM2, and RHM3[4]. 
While debate continues where exactly viruses straddle 
the line between living and nonliving organisms, they have 
not been left out of the nearly ubiquitous nature of 
rhamnose. For example, the nucleocytoplasmic large DNA 




and Acanthamoeba polyphaga mimivirus contain within their 
genome one or more genes coding for rhamnose biosynthetic 
enzymes[6]. A testament to the sometime bewildering host-
pathogen relationship when viruses are involved is the 
probable horizontal gene transfer between the Paramecium 
bursaria Chlorella virus (PBCV-1) and its host, neither a 
bacterium nor a mammal, of both bacterial and mammalian 
genes involved in rhamnose and fucose biosynthesis[16]. 
PBCV-1 was the first virus confirmed to encode its own 
enzymes for nucleotide sugar metabolism[16]. Several years 
later, both ATCV-1 and mimivirus would also have similar 
genes annotated and the resulting enzyme activity 
confirmed[6]. Rhamnose can be found alongside fucose in 
glycosylated structural proteins such as Vp54, which 
contribute to virus protease resistance and 
antigenicity[16]. Following the production of GDP-D-
rhamnose and GDP-L-fucose, the viral genome also contains 
the requisite genes for glycosyltransferases used to 
glycosylate the capsid proteins[6]. 
 The viral pathway differs slightly from previously 
mentioned examples of rhamnose biosynthesis. The pathway 
branches into two sections, leading to GDP-D-rhamnose and 




isomer of GDP-D-rhamnose. No epimerization reaction is 
required, as the starting sugar moiety is mannose rather 
than glucose. Mannose is a C-2 epimer of glucose, hence 
the epimerization step is preempted by virtue of the 
starting sugar. Thus, only two steps are required to 
produce GDP-D-rhamnose, both carried out by GDP-D-mannose 
4,6-dehydratase (GMD). Despite the singular name, this 
enzyme is bifunctional and catalyzes the NADP+ dependent 
dehydration, followed by the NADPH dependent reduction to 
form GDP-D-rhamnose. Following the first reaction by GMD, 
the product can also feed into the biosynthesis of GDP-L-
fucose. In keeping with the remarkable efficiency of viral 
genomes, the enzyme GDP-4-keto-6-deoxy-D-mannose 
epimerase/reductase is also bifunctional and has similar 
functions to the bacterial RmlC and RmlD. As in bacteria 
with xylo-hexulose being epimerized to lyxo-hexulose, so 
is the mannose moiety epimerized to galactose and 
subsequently reduced to the end product, in this case GDP-
L-fucose. 
  Fungi have evolved to use rhamnose in a wide variety 
of cellular functions. Glycoproteins, exopolysaccharides, 
hyphae in Rhynchosporium secalis, and rhamnomannans are 




utilization in fungi. Pathogenic species of fungi often 
include rhamnose functions including recognition and 
adhesion to a host. As polysaccharides, they play an 
important role in biofilm formation and protection against 
desiccation. Chestnut blight, Cryphonectria parasitica, 
secretes an exopolysaccharide with rhamnose as the 
terminal sugar moiety for modulating host-pathogen 
interactions. Nonvirulent strains of C. parasitica lack 
this exopolysaccharide. Magnaporthe grisea, a rice 
pathogen and causative agent of rice blast disease, is 
estimated to annually destroy enough rice to feed over 
sixty million people[17]. This biotrophic fungus 
proliferates inside plant tissues, concurrently damaging 
the rice and reducing yield. Botryotinia fuckeliana is a 
necrotrophic fungus which attaches to and kills its host 
by secretion of enzymes and toxics, invading tissues 
following the host’s death[17]. All three of these 
agriculturally relevant pathogens utilize rhamnose in 
multiple forms during their life cycle. Also, in the human 
pathogen responsible for candidiasis, Candida albicans, 
rhamnose it part of polysaccharides used for biofilm 




in pathogenicity among fungi. Indeed, over 200 fungi 
species are known to cause disease in humans. 
 The end product of the fungal rhamnose pathway is 
UDP-rhamnose, unlike bacteria where dTDP-rhamnose is the 
final result. In contrast to bacteria, the pathway is 
generally considered to being with an already charged UDP-
glucose instead of with the nucleotide diphosphate being 
attached to glucose. UG4,6-Dh, the homologue of RmlB, 
carries out the dehydratase function. However, the 
bacterial RmlC and RmlD activity are combined onto a 
single, large bifunctional enzyme, U4k6dG-ER, which 
catalyzes both the epimerization and reduction of UDP-4-
keto-6-deoxyglucose into UDP-rhamnose. 
 In keeping with human and agricultural interest in 
rhamnose, the environmentally friendly insect control 
agent produced by Saccharopolyspora spinosa, the 
spinosyns, are macrolides comprised of a 21-carbon 
tetracyclic lactone with two attached deoxy sugars: a tri-
O-methylated rhamnose and forosamine, a dimethyl amino 
sugar derived from the rhamnose pathway[19]. Rhamnose is 
attached first, followed by S-adenosyl-L-methionine (SAM) 
dependent methyltransferases leading to tri-O-methylation 




Only after the tri-O-methylation is complete is forosamine 
added at the 9-oxy position on the lactone. The spinosyns 
bind to nicotinic acetylcholine receptors and also act as 
γ-amino-butyric acid (GABA) neurotransmitter agonist. 
Insecticidal activity is by nervous system 
hyperexcitation.  
 While S. spinosa is a bacterium with the standard 
four step pathway to a nucleotide diphosphate charged 
rhamnose, the product of the dehydratase reaction also 
feeds into the spinosyn biosynthetic pathway. Gene 
duplication of the first two shared steps, gtt and gdh, 
results levels of spinosyn more than doubling[19]. This 
increased flux yields an increase in TDP-4-keto-6-deoxy-D-
glucose, the rate limiting substrate in both pathways. The 
excess not needed for cell wall production is utilized in 
increasing the production of spinosyns. By incorporating 
additional copies of gtt and gdh, the commercial yield 
greatly increased. This yield increase facilitates the 
usages and financial viability of the spinosyns, which 
having the benefits of high efficacy, a broad insect pest 





 The specific purpose, and whether that purpose is 
essential, correlates with the positioning of the four rml 
genes within the bacterial genome. In Escherichia coli, 
rhamnose is used as one of three sugar moieties in 
lipopolysaccharide[20]. While critical for infection, 
defects in dTDP-rhamnose biosynthesis are not lethal here. 
However, Streptococcus pyogenes has an absolute 
requirement for rhamnose in the production of over half of 
its cell wall. We observe in E. coli that the four genes 
are located adjacently in the same operon in the order B, 
D, A, C. Pseudomonas aeruginosa also displays the same 
gene adjacency and B, D, A, C order, with rhamnose again 
playing an important but non-essential role in glycolipid 
biosurfactant and lipopolysaccharide biosynthesis[21]. 
Again, rhamnose’s usage is necessary for infection but not 
survival. This positioning within the same operon and the 
same order is common in bacteria without a survival 
requirement for rhamnose production. In bacteria where it 
is an essential saccharide, the gene locations are 
typically dispersed throughout the genome. The rml genes 
in S. pyogenes have no obvious relationship to one another 
through genome placement. For example, rmlC and rmlD are 




epigenetic relationships are possible, none have been 
discovered to date. Of interest to note is that while 
sequence identity between the enzymes, such as RmlC, in E. 
coli and S. pyogenes is not particularly high, 29%, the 
sequence similarity is 58.6%. While the gene sequence and 
genome position vary considerably within bacteria, the 
amino acid sequence is functionally highly similar and 
crystal structures solved to date show little variation 
between species. As dTDP-rhamnose is the end product of 
the bacterial pathway regardless of the cellular 
destination of rhamnose, this is not unexpected. 
 Species of the Mycobacterium genus, from M. marinum 
to M. abscessus to the infamous M. tuberculosis, utilize 
rhamnose as a saccharide linker between peptidoglycan and 
galactan moieties of the arabinogalactan layer[13]. This 
is a unique feature of Mycobacteria. While bacteria across 
genera use, and in some cases require rhamnose, only 
Mycobacteria are known to utilize rhamnose to tether two 
layers of the cell wall together. While classified as 
Gram-positive, Mycobacteria contain features of both Gram-
positive and Gram-negative bacteria. Focusing on M. 
tuberculosis, the cell envelope is composed of three major 




capsule-like material, the mycolic acid-arabinogalactan-
peptidoglycan complex (MAPc), and the plasma membrane 
create a unique envelope that is highly resistant to both 































Figure 2: Diagram of M. tuberculosis cell wall[1] 
Reproduced with permission from publisher Elselvier, 




 Mycobacterium tuberculosis is a particularly 
ubiquitous infective agent, with an estimated one-third of 
the population currently colonized by it[24]. Fortunately 
for humans, most of those infected will remain carriers 
and never progress to an active infection. However, the 
large number of infected still leads to an average of over 
one million deaths a year[25]. A variety of factors, from 
being among the slowest growing of bacteria to a cell wall 
acting as a waxy barrier to antibiotics and environmental 
stressors, making this pathogen particularly difficult to 
treat[26]. It is mostly found in the eastern hemisphere, 
with emphasis on Sub-Saharan Africa. A complicating factor 
in treating tuberculosis is that a treatment regimen will 
last several months, creating issues with both patient 
compliance and cost. A latent infection is generally 
treated with isoniazid or in combination with 
rifampicin[27]. An active infection requires a more 
aggressive approach, with up to several antibiotics being 
combined to increase efficacy and to reduce the risk of 
developing antibiotic resistance. 
 The genetics of M. tuberculosis rhamnose biosynthesis 
follow the “essential” model, with the four rml genes 




relationship to each other. Each gene is a single, non-
redundant copy. As expected, the rml genes of M. 
tuberculosis are considerably similar to other species 
such as E. coli, P. Aeruginosa, and S. pyogenes. 
 The MAPc is comprised of cross-linked peptidoglycan, 
covalently bound to arabinogalactan chains via phosphoryl-
N-acetylglucosaminosyl-rhamnosyl units. α-alkyl and β-
hydroxy mycolic acids are esterified to the non-reducing 
ends of arabinan[28]. The biosynthesis of this complex 
realizes the convergence of many different pathways, 
including the non-mevalonate pathway for isoprenoid 
production. Starting with peptidoglycan, uridine 
diphosphate N-acetylglucosamine is converted through a six 
step process into uridine diphosphate N-acetylmuramic acid 
(MurNAc) pentapeptide. The isoprenoid undecaprenyl 
phosphate is produced through a six step process beginning 
with the condensation of pyruvate and glyceraldehyde-3-
phosphate. Undecaprenyl phosphate acts as a membrane 
acceptor, receiving the phospho-MurNAc-pentapeptide moiety 
of UDP-MurNAc-pentapeptide to create Lipid I. The addition 
of GlcNAc to the MurNAc residue of Lipid I leads to Lipid 
II, which is comprised of the completed disaccharide-




A2pm (or l-Lys)-d-Ala-d-Ala. Lipid II is carried by the 
ABC transporter enzyme flippase through the hydrophobic 
core of the cytoplasmic membrane to external sites for 
polymerization. The two major types of modifications are 
the formation of glycan chains by glycosyltransferases and 
crosslinking by transpeptidases, which also bind it to the 
preexisting peptidoglycan. 
The biosynthesis of the arabinogalactan layer begins 
with the transfer of GlcNAc-1-phosphate from UDP-GlcNAc to 
the terminal prenyl phosphate of peptidoglycan[29]. The 
terminal glucosamine is then rhamnosylated, forming the 
linker region between peptidoglycan and arabinan. This 
rhamnose residue is produced from a four step pathway, 
followed by the Wbbl-catalyzed rhamnosyl transferase 
reaction to link it to the glucosamine.  
The dTDP-rhamnose is the charged form of rhamnose 
used for the rhamnosylation reaction. The pathway begins 
with the enzyme RmlA, functioning as a D-glucose-1-
phosphate thymidylyltransferase[30]. RmlA transfers 
deoxythymidine phosphate from deoxythymidine triphosphate 
to D-glucose-1-phosphate, forming dTDP-glucose. RmlB is a 
dTDP-D-glucose-4,6-dehydratase, catalyzing the NAD+ 




residue, followed by the removal of a water via 
dehydration and forming dTDP-6-deoxy-D-xylo-4-
hexulose[31]. RmlC has no cofactor, functioning as an 
epimerase of the 3 and 5 positions of the xylo-4-hexulose 
residue. In the penultimate step, rhamnose is formed 
through the RmlD-catalyzed reduction of the C4 keto group 
of dTDP-6-deoxy-L-lyxo-4-hexulose into dTDP-rhamnose. This 
charged rhamnose is attached to the added terminal 
glucosamine of peptidoglycan, completing the linker with 











 The RmlA reaction follows a sequential ordered bi bi 
mechanism in which the substrates bind in an obligate 
order, followed by the reaction and the products departing 
in an obligate sequence[20]. Structural studies with a 
bound dTTP suggest the formation of a covalent 
intermediate with dTMP does not occur and mechanistic 
experiments show the dTTP binds first[30]. This is 
consistent with an SN2 type reaction, with dTTP binding to 
the protein, followed by glucose-1-phosphate (G1P). G1P 
acts as a nucleophile, attacking the α-phosphate of dTTP 
and the β/γ phosphates leave as pyrophosphate. The reverse 
reaction is possible, with the α-phosphate of dTDP-D-
glucose undoing a nucleophilic attack by pyrophosphate and 
displacing G1P. 
 RmlB is a three-step mechanism, with oxidation 
following by dehydration and finished by reduction. 
Structural studies have elucidated tyrosine as beginning 
the reaction as a base by extracting a proton from the C4’ 
hydroxyl on the glucosyl residue of dTDP-glucose, followed 
by the concomitant abstraction of a hydride by NAD+ from 
the C4 position. This creates the 4-ketosugar that is key 




dehydration step to occur. An aspartate in the protonated 
state makes contact with the C6’ hydroxyl, donating a 
proton to O6 through a hydrogen bond. O6 abstracts this 
proton, cleaving the C6-O6 bond with water as the leaving 
group. The final step involves the newly formed NADH 
transferring a hydride back to the glycosyl C6’, causing a 
configuration inversion at C6 and a proton addition to C5. 
The deprotonated tyrosine is regenerated and dTDP-4-keto-
6-deoxy-D-glucose is produced. Allard et al solving the 
structure of RmlB and characterizing it was paramount to 
determining the mechanism of the enzyme[32, 33]. 
 The third step, RmlC, catalyzes a double 
epimerization at the C5’ and C3’ positions[34]. While the 
mechanism has not been definitively proven to date, a 
suggested mechanism based on structural and biochemical 
data suggests the C5’ position is epimerized first, 
although the data does not exclude the possibility of a 
primary C3’ epimerization. The key residues are histidine 
and tyrosine, with histidine acting as a catalytic base 
for both epimerizations and tyrosine donating a proton to 
the C5’ position. To prevent the energetically unfavorable 
C6’ O1’ diaxial and C6’-histidine clash, the sugar flips 




epimerization the twisted boat conformation is most 
energetically favorable, with C4’ moving upward through 
the ring plane[35]. Histidine abstracts a hydride from 
C3’, leading to an oxyanion forming at C4’. The oxyanion 
reverts to a carbonyl following a second epimerization, 
forming dTDP-6-deoxy-L-lyxo-4-hexulose. 
 The final step is an NADPH-mediated reduction 
catalyzed by RmlD. This enzyme utilizes a catalytic triad 
of threonine and a conserved tyrosine-XXX-lysine sequence. 
This triad in conjunction with the presence of a Wierenga 
motif (glycine-XX-glycine-XX-glycine) in a Rossmann fold 
classifies RmlD as a member of the 
reductase/epimerase/dehydrogenase superfamily. The 
catalytic triad protonates the carbonyl and deprotonates 
the hydroxyl via tyrosine and threonine, respectively. The 
lysine bonds with the ribosyl unit of NADPH and lowers the 
pKa of threonine. 
All five of these reactions are essential and cannot 
be complemented with other enzymes in the M. tuberculosis 
proteome. Humans do not have any known biosynthetic 
pathway for or utilization of rhamnose. Human gut flora 
are known to metabolize rhamnose but no outcomes other 




from intestinal fermentation, and gut flora growth are 
experienced. As such, the pathway has been considered a 
drug target since its elucidation. Additional benefits of 
rhamnose targeting in M. tuberculosis, and all bacteria, 
is that rhamnose cannot be supplemented[13]. Only the 
charged form, dTDP-rhamnose and other nucleotide variants, 
can be utilized and must be produced via the rml pathway. 
As suggested by gut flora growth, bacteria can take up the 
rhamnose saccharide via a transporter and use it as a 
carbon source. However, rhamnose catabolism and dTDP-
rhamnose biosynthesis are separate functions with no 
crossover. dTDP-rhamnose is formed from D-glucose-1-
phosphate, converted from D-glucose. It is this glucose 
that is ultimately converted to the rhamnose residue of 
dTDP-rhamnose. 
Each of the four rml genes and wbbl have been 
extensively studied to determine their essentiality. The 
most common method documented is the use of a chromosomal 
knockout of the gene in question in conjunction with a 
copy on a temperature sensitive plasmid. Each gene has 
been tested in a Mycobacterium smegmatis mc2155 model, in 
all cases with a functional copy of the corresponding 




tuberculosis gene was able to complement the loss of the 
M. smegmatis chromosomal copy. Qu et al created an M. 
smegmatis strain with a chromosomal knockout of rmlA, with 
the M. tuberculosis rmlA on a plasmid capable of curing 
when grown at 42°C[36]. When shifted from 30°C to 42°C, 
after 24 hours cell density, as determined through A600, 
began dropping and continued to decrease until the end of 
the experiment. No growth defects were observed in the 
comparative sample kept at 30°C. Scanning electron 
microscope showed cells with severe morphological defects, 
including lysed cells. Li et al performed a nearly 
identical experiment to test for the essentiality of rmlB 
and rmlC. In both cases, the chromosomal copy resulted in 
a loss of viability which could be rescued by a M. 
tuberculosis copy on a temperature sensitive plasmid.  Ma 
et al created the same type of experiment for rmlD, 
showing that the knockout resulted in a loss of viability. 
The final step for incorporation into the cell wall, wbbL, 
was also tested in Mills et al, showing lethality in 
absence of complementation by the M. tuberculosis 
copy[37].  
In the early stages of drug development, a method to 




important to finding compounds with inhibitory capability. 
It is fortuitous that each of the four rml enzymes are 
soluble and active when expressed in E. coli. Assays have 
been optimized for measuring the activity of each enzyme. 
While substrates are commercially available for RmlA and 
RmlB, RmlC and RmlD must be coupled to RmlB as their 
substrates are either not commercially available or too 
unstable to synthesize. RmlC cannot be easily measured by 
itself, requiring the subsequent RmlD reaction to assay 
its activity. Initially, RmlA was measured by endpoint 
assays using malachite green to measure phosphate 
production[38]. However, real time assays are now 
available with the advent of a fluorescent phosphate 
binding protein. RmlB can be assayed by measuring NAD+ 
turnover. RmlC and RmlD are measured by RmlD’s NADPH 
turnover, requiring coupling with RmlB to produce the RmlC 
substrate. Ma et al has developed a microtiter assay to 
allow for high throughput screening the terminal three 
enzymes, which has a strong possibility of improvements 
allowing the entire pathway to be screened 
simultaneously[39]. 
Indeed, assay development has led to multiple high 




resulting in novel inhibitors being discovered. Compounds 
with varying degrees of efficacy for each enzyme are 
known, although not all have been tested against the M. 
tuberculosis enzymes. Given the high degree of homology of 
the rml enzymes, it is not unreasonable to predict that an 
inhibitor of one bacterium’s RmlA would have some efficacy 
against the M. tuberculosis RmlA. Alphey et al conducted a 
high throughput screen of the Pseudomonas aeruginosa RmlA 
and discovered nanomolar inhibitors with a scaffold based 
on a pyrimidinedione core[40]. These are particularly 
unique in that they are allosteric inhibitors with 
competitive inhibition curves. The structure of P. 
aeruginosa RmlA has also been solved and 
characterized[41]. RmlA is known to be allosterically 
inhibited by the pathway end product, dTDP-rhamnose, 
through a second binding site. Crystal structures of the 
inhibitors bound to the P. aeruginosa RmlA suggest the 
mechanism of inhibition is by preventing the 
conformational change required for the bi-bi mechanism to 
function[40]. Other RmlA structures further support 
this[42]. The allosteric site amino acids which interact 




tuberculosis, suggesting a strong likelihood of both some 
level of efficacy and a similar binding motif. 
RmlB has prior inhibitor screening as well in a non-
tubercular bacterium, Streptococcus mutans. Mere months 
before this writing, van der Beek et al published results 
of a Maybridge library high through screen resulting in a 
few inhibitors, with one designated as a lead molecule to 
due to no cytotoxicity up to 15mM against U937 human 
monocytic cells[43]. The lead molecule, 5-(4-
Chlorophenyl)-2-furoic acid, is easily obtainable and 
inexpensive, with its small size (222g/mol) creating 
possibilities for modifications while remaining amenable 
to the active site. The compound has only moderate 
micromolar efficacy against the enzyme and cells but to 
date is the only confirmed RmlB inhibitor published. As 
with RmlA, the S. mutans RmlB is highly similar to M. 
tuberculosis and would likely have some degree of 
inhibition. Crystal structures of multiple examples of 
RmlB have been published in other organisms[44]. 
The third step in the pathway, RmlC, has been 
considered the most ideal of the four for drug targeting 
due to not requiring a cofactor. Practical considerations 




also used by many human enzymes is a reasonable concern. 
RmlA’s substrate is D-glucose-1-phosphate, ubiquitous in 
the human body. RmlB and RmlD both utilize NAD+ and NADPH, 
respectively. Cross reactivity with a human enzyme would 
pose a threat to a compound’s ascension to becoming a 
commercial antibiotic. RmlC uses no cofactors and its 
substrate, dTDP‐4‐keto‐6‐deoxyglucose, has not been found in 
humans. RmlC was screened against a library of over 
200,000 compounds by Sivendran et al, yielding a new class 
of inhibitors[1]. The triazinoindol-benzimidazolones have 
remarkable efficacy against M. tuberculosis RmlC, with the 
most potent analog having an IC50 of 120 nM[1]. The MIC 
against cells is calculated to be 9µg/ml, putting it close 
to the commercial antibiotics rifampin and ethambutol. 
Cytotoxicity testing against human aortic endothelial 
(HAE) cells yielded an IC50 of 75µM. Only a single analog 
was tested against HAE cells, so it is unknown if the 
other analogs would display a lower cytotoxicity. 
Regardless, this is an impressive beginning to determining 
the viability of RmlC as a candidate for an antibiotic. 
The indole ring is a well-documented moiety in many 
biologically active natural and synthetic products, with a 




inflammatories, HMG-CoA reductase inhibitors, 
phosphodiesterase inhibitors, and cannabinoid receptors 
agonists. 
The final enzyme in the pathway in Mycobacterium 
tuberculosis, RmlD, has benefited from a virtual screen of 
a library. In addition, the structure of RmlD in other 
organisms offers a homology model for this screening[45]. 
Wang et al conducted a virtual screen of a 140,000 
compound library to probe for inhibitors[2]. As the M. 
tuberculosis RmlD structure was not known, a homology 
model using the Salmonella enterica serovar Typhimurium 
structure. Again, the high degree of conservation across 
species has proven a boon for drug design. Structure-based 
drug design has long been a process for developing new 
antibiotics by comparing the activity of compounds which 
are similar in structure but through slight differences 
provide considerable data for future alterations[46]. 
Compounds with favorable predicted binding energies were 
funneled through multiple levels of additional screening, 
such as modeled interactions with essential active site 
residues with the idea resistance would be less likely to 
develop. Following this, compounds underwent a final round 




five, which states: no more than 5 hydrogen bond donors, 
no more than 10 hydrogen bond acceptors, a molecular mass 
less than 500 daltons, and a logP/ClogP not greater than 
5[47]. They are a rule of thumb regarding the “drug-
likeness” of a compound. The final four compounds are 
structurally similar, with three being analogs of each 
other. The results were encouraging with a caveat. While 
the two most potent compounds enzymatically had IC50’s as 
low as the nanomolar range, they had only moderate 
efficacy against whole cells. The other two compounds had 
excellent efficacy against whole cells, but were only 
moderate enzymatic inhibitors. It would not be 
unreasonable to suggest this could be reconciled through 
crystal structures and synthetic chemistry, resulting in a 
compound with excellent enzymatic and ultimately high 
whole cell potency. 
By far the most common antibiotic class used to treat 
infections is the β-lactam, which until 2003 accounted for 
over half of antibiotic sales in the world[48]. While 
molds have anecdotally been observed to inhibit bacterial 
growth and even used to treat wounds, it was not until 
Alexander Fleming serendipitously discovered penicillin in 




world’s leading antibiotic[49, 50]. After years of 
investigation it was discovered that β-lactams target 
peptidoglycan biosynthesis in bacteria, the mesh-like 
layer in the cell wall found in all known bacteria except 
for the families Chlamydiaceae and Mycoplasmataceae[51-
53]. 
The general structure of a gram-positive bacterial 
cell wall is an inner membrane surrounded by a layer of 
peptidoglycan, with gram-negative bacteria having a 
thinner peptidoglycan layer with an outer membrane. The 
peptidoglycan layer varies in thickness, with gram-
positive bacteria having a much thicker layer comprising 
half or more of the cell envelope while only comprising 
about 10% of gram-negative cell envelope. The larger 
amount of peptidoglycan in gram-positive bacteria allows 
for the eponymous gram staining technique to distinguish 
them from gram-negative bacteria through crystal violet 
and iodine forming a complex within the framework, 
preventing the dye from washing out. Mycobacterium 
tuberculosis is unique in that the amount of peptidoglycan 
in its cell wall would place it squarely within gram-
positive, however it does not readily stain due to a 




cell wall preventing the dye from entering the cell. 
Instead, when M. tuberculosis is suspected an acid-fast 
stain such as Ziehl-Neelsen or fluorescent stain such as 
auramine is used. 
As with any layer in the cell wall, major disruption 
of this peptidoglycan layer is invariably lethal. In 
addition to influencing the shape of the bacterium, 
peptidoglycan also provides protection against sheering 
forces and osmotic stress. The aptly named penicillin-
binding proteins (PBPs), the targets of β-lactams, are the 
penultimate architects of this framework by at least two 
of three mechanisms: D-alanine carboxypeptidase, 
peptidoglycan transpeptidase, and peptidoglycan 
endopeptidase. The enzymes have bifunctionality, with an 
N-terminal transglycosylase domain involved in the 
formation of linear glycan strands and a C-terminal 
transpeptidase domain involved in cross-linking of the 
peptide subunits that is the target of β-lactams. An 
active site serine is conserved in all members of the PBP 
family. 
 Given the ancient biological origins of β-lactams, it 
is unsurprising that an evolutionary arms race has 




attacking bacteria. Bacteria have responded with their own 
defensive molecule, the enzyme β-lactamase. The suffix 
eloquently reveals the function: breaking down β-lactams. 
These enzymes catalyze the hydrolysis of the namesake 
chemical moiety, the β-lactam ring. This four-membered 
cyclic amide is an essential component of this antibiotic 
class and upon hydrolysis, is rendered ineffective. 
Bacteria expressing β-lactamases thus have an evolutionary 
advantage over other bacteria when encountering β-lactam-
producing fungi. The genes coding for these enzymes have 
been sequenced and bear a degree of similarity to PBPs 
such that they are hypothesized to have evolved from them. 
Indeed, one can follow the trail of crumbs to this 
conclusion. By simply comparing the structure of 
penicillin to the D-alanine-D-alanine terminus of the 
transpeptidase substrate, a remarkable structural mimicry 







It follows that an enzyme evolved from a PBP would 
retain a similar level of substrate recognition. A non-
essential enzyme with the same type of substrate 
recognition as a PBP could then serve as a defensive line, 
binding to β-lactams in lieu of them inhibiting the PBPs. 
Indeed, β-lactamases are often secreted to hydrolyze β-
lactams before they can enter the cell. This insult has 
not been unchallenged, with evolution resulting in 
clavulanic acid from Streptomyces clavuligerus[54]. 
Clavulanic acid has negligible bactericidal activity but 
is able to act as a suicide inhibitor against many β-
Figure 4: Mimicry between penicillin and D-ala-
D-ala  
Structural comparison of Penicillin with the 





lactamases. Upon covalently binding to the active site 
serine, a rearrangement occurs and creates a more reactive 
imine. This imine can follow two paths. The first involves 
the imine stabilizing upon tautomerization to an enamine, 
resulting in a transient inhibition. The second path 
occurs when a second active site nucleophile is acylated 
by the imine, resulting in a cross-linked enzyme, leading 
to irreversible inactivation. As such, clavulanic acid is 
co-administered with a bactericidal β-lactam. In addition 
to increasing the efficacy of the bactericidal activity of 
the other β-lactam, this also allows for antibiotics that 
previously had limited use against resistant bacteria to 
become effective again and permits safer and less costly 
antibiotics to be used. 
 Mycobacterium tuberculosis is renowned for being able 
to evade β-lactams due to its promiscuous broad spectrum 
class A β-lactamase, BlaC. To date, there is no FDA 
approved β-lactam for treating tuberculosis. Much research 
over the years has been conducted on BlaC in an attempt to 
understand how it is able to readily hydrolyze approved β-
lactams, including the first crystal structure by Wang et 
al in 2006[55]. Upon structural elucidation is became 




allowed the active site to accommodate β-lactams of 
varying size and shape. Recent advances have shown the 
newer penem and carbapenem classes of β-lactams have 
clinical relevance and have gained approval in other 
countries such as Japan. 
 Another pathogenic bacterium known for its ability to 
shrug off antimicrobials is the Gram-negative Pseudomonas 
aeruginosa. Particularly noteworthy is that, while 
individual strains vary in susceptibility to different 
antibiotic classes, only the fluoroquinolone class is 
generally effective against all strains. However, 
fluoroquinolone-resistant strains are increasing in 
frequency in clinical settings. The low antibiotic 
susceptibility is widely attributed to the presence of 
multidrug efflux pump genes (i.e. mexAB, mexXY) and the 
low permeability of the cell wall. P. aeruginosa is also 
capable of rapidly acquiring resistance through horizontal 
gene transfer and chromosomal mutations. Biofilm formation 
further restricts the uptake of antibiotics. Cystic 
fibrosis (CF) patients are particularly vulnerable to P. 
aeruginosa infection and this pathogen is the single 




 Pseudomonas aeruginosa is a Gram-negative bacterium 
capable of infection plants and animals. Diagnostic tests 
categorize it as citrate, catalase, and oxidase positive. 
A hallmark characteristic of P. aeruginosa is the blue-
green color most strains exhibit from pyocyanin and 
pyoverdine biosynthesis. Pyocyanin is an important 
virulence factor, capable of generating reactive oxygen 
species. Strains defective in pyocyanin biosynthesis 
exhibit a marked decrease in the ability to initiate an 
infection. Pyoverdine is able to assist in the uptake of 
iron from the extracellular environment and mediates 
exotoxin A. It is a facultative anaerobe, capable of using 
nitrate and nitrite as a terminal electron acceptor. While 
found virtually everywhere in the environment, P. 
aeruginosa is more an opportunistic pathogen and is more 
common among the young, old, and otherwise physiologically 
compromised patients. It is especially known for a high 














The Mur pathway is the first committed step to 
peptidoglycan biosynthesis, with MurA through MurF 
resulting in the UDP-MurNAc-pentapeptide followed by MraY 
and MurG to produce Lipid I and Lipid II, 
respectively[57]. The first six steps are comprised of 
MurA, a transferase, MurB, a reductase, and the four ATP-
dependent ligases, MurC-MurF. They are all highly 
conserved across bacterial  
species and possess no counterparts in eukaryotes, who 
lack peptidoglycan. Each gene is a single copy and 
generally found in separate operons. 
This study will primarily discuss the first step, 
MurA, in Pseudomonas aeruginosa. Denoted as UDP-N-
acetylglucosamine 1-carboxyvinyltransferase (EC 2.5.1.7), 
MurA catalyzes the transfer of the enolpyruvate moiety of 
phosphoenolpyruvate (PEP) to the 3’-OH hydroxyl group of 
UDP-GlcNAc, resulting in phosphate as leaving group[58]. 
In a deviation from the expected use of the high energy P-
O bond of the phosphate in a reaction involving PEP, the 
C-O bond is instead cleaved. The mechanism entails an 
“induced fit” in which UDP-GlcNAc must bind MurA before 
PEP[59]. The reaction follows an addition-elimination 




intermediate state where the two substrates are covalently 
linked with the PEP C-2 assuming a tetrahedral 
configuration and C-3 becomes a methyl group. The 
resulting carboxyvinyl ether forms the starting point for 
the addition of the five amino acids in the terminal 
pentapeptide following MurB-MurF, resulting in UDP-MurNAc-
pentapeptide. It is not uncommon for the first committed 
step of a pathway to be feedback inhibited by later 
products. Indeed, E. coli MurA is inhibited by the product 
of MurB, UDP-MurNAc. Given the high degree of similarity 
between MurA enzymes, it can be predicted that other 
species would face the same feedback inhibition. murA was 
confirmed in 1995 to be essential following a chromosomal 
deletion in conjunction with an arabinose inducible 
plasmid containing a copy of murA. Growth of cells 
containing the murA deletion was dependent on the presence 
of arabinose to induce expression of murA from the 
plasmid. 
 The phosphate produced by the reaction initially left 
the assay amenable only endpoint monitoring by malachite 
green[38]. Toxic by itself, the malachite green must then 
be activated by sulfuric acid. Fortunately, advances have 




dangerous chemicals. Two modern methods include a purine 
nucleoside phosphorylase which utilizes the inorganic 
phosphate to split the bond between the phospho-ribose 
sugar and the nucleoside, allowing for monitoring at 360 
nm[60]. The second method uses a synthetic phosphate-
binding enzyme, which fluoresces upon binding. 
 Following the production of UDP-MurNAc-pentapeptide, 
the membrane stage of peptidoglycan biosynthesis begins 
with MraY[61]. It catalyzes the transfer of MurNAc 
pentapeptide from UDP-MurNAc-pentapeptide to the plasma 
membrane-bound lipid carrier undecaprenol phosphate to 
form Lipid I. Lipid II is formed following the addition of 
a terminal GlcNAc residue. MurJ is a recently discovered 
flippase which carries Lipid II through the plasma 
membrane, “flipping” it to face the exterior of the cell.  
 Upon reaching the periplasm Lipid II splits into 
undecaprenol, which is recycled for future Lipid I 
production, and the GlcNAc-MurNAc-pentapeptide (GM-PP) 
begins the steps to integrate into the peptidoglycan 
framework[61]. A glycosyltransferase catalyzes the 
polymerization of the GM-PP to the nascent peptidoglycan 
chain, with a DD-transpeptidase attaching the new chain to 




LD-carboxypeptidases, with DD- and LD-endopeptidases 
cleaving crosslinks. These cleavages allow the existing 
peptidoglycan to incorporate the new residues. The three 
LD-transpeptidases catalyze the formation of 3-3 
peptidoglycan cross-links, attachment of the outer-
membrane lipoprotein, and binding D-amino acids. 
 These insertions by themselves would only thicken the 
sacculus without elongating it. The growth of 
peptidoglycan must occur in a way that maintains a 
consistent thickness, else the bacteria would enlarge 
without end[62, 63]. A series of hydrolases, which 
combined are capable of cleaving nearly every 
physiological glycoside and amide bond, cleave 
peptidoglycan such that new residues can insert without 
increasing the thickness of the sacculus. A highly 
controlled regulatory framework exists, whereby 
peptidoglycan biosynthesis and hydrolysis is regulated by 
having the machinery form loosely-bound multienzyme 
complexes. This ensures minimal hydrolase activity except 
where biosynthetic enzymes are also present. These same 
hydrolases are indirectly involved in the activity of β-
lactams. With the balance between building and hydrolysis, 




results in the scales tipping to hydrolysis and result in 
a breakdown of the peptidoglycan framework. Knockouts of 
individual hydrolases show no lethality, however this can 
result in an altered morphology as each hydrolase has a 
specific bond it cleaves. 
 As would be expected of such a large portion of the 
cell wall, peptidoglycan biosynthesis is regulated in by 
connections multifactorial. Chief among them is cell 
growth and division. FtsZ is a tubulin-like protein which 
is a major regulator of bacterial cell division and forms 
a ring around the midcell designated the Z ring before 
cell division. Enzymes involved in Lipid II and 
peptidoglycan biosynthesis are recruited to the Z ring. 
When cell division begins FtsZ constricts at the septum, 
causing local stretching of the sacculus. This force 
promotes peptidoglycan biosynthesis at the septum where 
the two daughter cells separate 
 Targeting peptidoglycan is not the domain held solely 
by β-lactams. First discovered in 1969 from a soil culture 
of Streptomyces fradiae, the antibiotic fosfomycin acts as 
a suicide inhibitor of the enolpyruvyl transferase at the 
beginning of the peptidoglycan biosynthesis pathway, MurA. 




that is strained and thus highly reactive. Confirmed 
through a crystal structure, it irreversibly alkylates the 
active site cysteine 115, inactivating MurA. Despite this 
high level of reactivity, fosfomycin is excreted in the 
urine unchanged. This suggests a considerable degree of 
specificity and little or no cross-reactivity with other 
enzymes. As it is primarily excreted in the urine in an 
unchanged state, this concentrates fosfomycin in the 
bladder and makes it a common prescription for treating 
urinary tract infections. It is so well tolerated by 
patients that it is often given as a “megadose”, allowing 
the simplest possible regimen for high levels of 
compliance.  It has been successfully explored as a 
fosfomycin/tobramycin combination inhalation therapy for 
CF patients[64]. These characteristics have led to it 
being evaluated for treating infections not previously 
considered. 
 Fosfomycin is not an outlier in the evolution of 
resistance mechanisms. P. aeruginosa, and other bacteria 
such as Klebsiella pneumoniae, express the enzyme FosA. 
FosA is a metal-dependent transferase that catalyzes the 
conjugation of glutathione to fosfomycin. This inactivates 




lactamase, as enzyme-catalyzed antibiotic degradation. The 
multidrug efflux pumps are able to remove fosfomycin from 
the cell. The active site of MurA is very large in order 
to accommodate both UDP-NAc and phosphoenolpyruvate, 
leading one to believe a mutation is unlikely to prevent 
such a small (138 g/mol) molecule from entering. The 
active site cysteine is an important catalytic residue. 
However, this cysteine can mutate to an aspartate, 
rendering the mechanism of fosfomycin ineffective. The 
fitness cost is minimal, with the aspartate able to take 
over cysteine 115’s role in product release. Indeed, 
Mycobacteria and Chlamydia commonly have this variation 
innately and fosfomycin is not effective in treating those 
infections. The uptake of fosfomycin is also a subject of 
resistance mutations, with the glycerol-3-phosphate 
transporter glpT required for its introduction into the 
cell. glpT possesses relatively low specificity, able to 
readily transport very small (<200 dalton) molecules 
possessing a phosphate or phosphate mimic, including 
aresenate, inorganic phosphate, and fosfomycin. P. 
aeruginosa is known to develop mutations in glpT, 
preventing the uptake of fosfomycin. Between multidrug 




P. aeruginosa is well equipped to meet the challenge of 
fosfomycin specifically and antibiotics in general. 
 Fosfomycin remains an effective treatment in certain 
circumstances but alternative inhibitor types that are not 
affected by FosA or the active site cysteine mutation 
present an attractive option. Many variations of 
fosfomycin have been evaluated but none have been approved 
for clinical use. MurA is a well validated target and 
offers possibilities beyond cysteine modification, which 
carries the potential risk of cross-reactivity. Terreic 
acid is a natural product from the fungus Aspergillus 
terreus that is able to covalently modify cysteine 115 and 
inhibit the reaction[65]. However, overexpression of MurA 
protected E. coli against fosfomycin but not terreic acid, 
suggesting that the antimicrobial effect of the compound 
is due to hitting multiple targets[66]. Alternate routes 
to inhibiting MurA activity such as a competitive 
inhibitor or a substrate mimic that can enter the pathway 
via MurA and inhibit thusly. Examples of both have been 
discovered, including an unusual compound which suspends 
the induced fit mechanism and obstructs the transition 




The tuliposides and tulipalins are derived from tulip 
anthers in the families Liliaceae and Alstroemeriaceae. An 
acidic environment results in the conversion of a 
tuliposide to its respective tulipalin and is speculated 
that the acidis organelles of the tulip anthers catalyze 
this conversion upon tissue damage by a microbial attack. 
The tulipalins mimic phosphoenol pyruvate and are able to 
form a MurA-catalyzed adduct with UDP-GlcNAc, resulting in 
a product nearly identical to the normal product, UDP-
GlcNAc-enolpyruvate[67]. It would not be unreasonable to 
suspect that this adduct generates a negative downstream 
effect such as inhibiting MurB. Chemical synthesis of 
these compounds has allowed for their production in house 
as opposed to the more laborious extraction from plant 
matter[68-70]. 
Another example of Nature’s genius is the molecule 
cnicin, from Cnicus benedictus. A sesquiterpene lactone 
containing a phosphoenolpyruvate mimic, it is able to 
enter MurA and in an enzyme-catalyzed reaction, form an 
adduct with UDP-GlcNAc to mimic the product[71]. 
Unfortunately, cnicin exhibits considerable toxicity to 




Chapter II of this study will detail the four dTDP-
rhamnose biosynthetic enzymes in Mycobacterium 
tuberuculosis, with emphasis on RmlC. Known M. 
tuberculosis rml inhibitors will be further evaluated, 
including crystal structures, cytotoxicity studies, and a 
murine pharmacokinetic model. New inhibitors against M. 
tuberculosis rml enzymes will be detailed. At the 
beginning of each chapter there will be a short background 
more specifically related to the respective project. 
Chapter III of this study will focus on the 
Pseudomonas aeruginosa MurA, focusing on crystallographic 
evaluation of the enzyme with regard to substrate, 
product, and inhibitors of various classes. While MurA has 
been highly characterized in other organisms, the 
pseudomonal enzyme has had no structural studies published 
to date and only some enzymatic assessments. The efficacy 
of these various classes of inhibitors was also tested 










STRUCTURAL AND FUNCTIONAL INSIGHTS INTO dTDP-RHAMNOSE 





 The Mycobacterium tuberculosis cell wall contains 
targets to several FDA approved antibiotics and continues 
to be evaluated for viability of as yet unutilized 
targets. The rhamnose biosynthetic pathway yields a 
product which forms the critical junction between the 
peptidoglycan and outer cell wall. Each of the four steps 
have been determined to be essential in Mtb. Sivendran et 
al discovered via high throughput screening a new class of 
molecules, the triazinoindol-benzimidazolones, that are 
highly effective against the third step, rmlC, and whole 
cells. A docking analysis was performed yielding two 
theoretical conformations. We have taken this class of 
compounds and further expanded the analysis with cocrystal 
structures, elucidating the exact mode of binding and 
offering insight into the potency or lack thereof with 




triazinoindol-benzimidazolones as potential antibiotics, 
we have evaluated the entire series for cytotoxicity 
against human dermal fibroblasts. Additionally, we have 
assessed the lead compound within the triazinoindol-
benzimidazolones for kinetic solubility, plasma stability, 
plasma protein binding, and with hepatic microsomes. 
Finally, our lead compound has been given orally and 





dTDP-rhamnose biosynthesis in Mycobacterium 
tuberculosis presents an as yet untested target pathway in 
an animal model or clinical setting. β-lactams, 
vancomycin, capuramycin, D-cycloserine and isoniazid all 
target different points of cell wall biosynthesis[73, 74]. 
With the increasing spread of multi-drug resistant M. 
tuberculosis, scientists the world over are simultaneously 
researching drug targets in an attempt to outpace 
evolution. Previous studies reveal each of the four steps 
are individually essential to the survival of M. 




rhamnosyl linker between peptidoglycan and arabinogalactan 
may prove fruitful in developing a novel antibiotic for 
real world use. 
 The third step, rmlC, is considered the most ideal 
target in the pathway due to the distinctiveness of the 
substrate from anything found in the human body and that 
it requires no cofactors, which would theoretically result 
in a decreased likelihood that a compound would disrupt a 
human enzyme that utilizes a shared cofactor through an 
interaction with the cofactor binding pocket[76]. 
 Triazinoindol-benzimidazolones inhibit rmlC through a 
competitive partial substrate/product mimicry, adopting 
the same pi-pi interaction with Tyr138 that exists between 
Tyr138 and the thymine moiety in the substrate and pathway 
end product. However, rather than interacting with the 
deeper catalytic residues in the active site the 
triazinoindol-benzimidazolones sit at the mouth of the 
active site. 
 Taking the initial screening results from Sivendran, 
we further evaluated analogs to determine the viability of 
substitutions in the triazinoindol moiety[1]. We also 
tested the compound stability, kinetic solubility, plasma 




series. In addition, bioavailability in an oral murine 
model and serum mean residual time in an intravenous model 
were measured. 
 The triazinoindol-benzimidazolones demonstrate 
remarkable stability, with no detectible degradation 
following a DMSO stock being stored at room temperature 
for one week. However, the low kinetic solubility 
suggested that oral bioavailability would be an issue. 
This was supported by results in an oral murine model 
showing absorption far below the determined MIC. 
 
MATERIALS AND METHODS 
 
Cloning, expression, and purification 
 
 Wild-type RmlA, RmlB, and RmlD were amplified from M. 
tuberculosis H37Rv genomic DNA using Phusion polymerase 
from New England Biolabs and inserted into the NdeI and 
XhoI sites in pET30b. Wild-type RmlC was amplified from M. 
tuberculosis H37Rv genomic DNA using Phusion polymerase 
from New England Biolabs and inserted into the NdeI and 




N-terminal hexahistine tags, respectively. Sequences were 
confirmed by Eton Bioscience.  
Plasmids were transformed into the Invitrogen E. coli 
BL21 (DE3) strain. To produce the protein, the bacterial 
cultures were grown at 37°C at 180 rpm in LB medium until 
an OD600 of 1.0 was reached. Following cooling to 20°C for 
60 minutes, the cultures were induced with 1.0 mM 
isopropyl-β-D-thiogalactoside. The cells were incubated 
overnight at 20°C, harvested and resuspended in lysis 
buffer (10% glycerol, 100 mM NaCl, 25 mM (NH₄)₂SO₄, 10 mM 
imidazole, 20mM HEPES pH 7.4, and 0.5 mM TCEP). Cells were 
disrupted via French Press at 20,000 PSI and the insoluble 
cellular material was removed by centrifugation at 15,000 
rpm for 1 hour.  
RmlA, RmlB, RmlC, and RmlD were purified using Ni-NTA 
affinity chromatography in a gravity column through 
multiple volumes of wash lysis buffer until eluent samples 
no longer produced a visible color change with Bradford 
protein quantification reagent, indicating washing was 
complete. Proteins were eluted with elution buffer (5% 
glycerol, 50 mM NaCl, 25 mM (NH₄)₂SO₄, 200mM imidazole, 
10mM HEPES pH 7.4, and 0.5 mM TCEP) until eluent samples 




protein quantification reagent, indicating elution was 
complete. Samples were then concentrated using Millipore 
Amicon Ultra-15 centrifugal filter units and injected onto 
a S200 size exclusion chromatography column. Peaks 
corresponding to the target protein were collected and 
concentrated to 10 mg/mL, 8 mg/mL, 20 mg/mL and 10 mg/mL 
for RmlA, RmlB, RmlC, and RmlD, respectively. Individual 
aliquots of purified protein were stored at -80°C until 
needed. Cloning of RmlA was originally done with an N-
terminal his-tag. However, the N-terminal his-tag resulted 
in an insoluble protein. 
 
Size exclusion chromatography 
 
The molecular weight of rmlC in solution was 
determined by size-exclusion chromatography using a 
Superdex 200 GE Healthcare 16/60 column. The column was 
calibrated with aprotinin (6.5 kDa), carbonic anhydrase 
(29 kDa), conalbumin (75 kDa), catalase (232 kDa), and 
thyroglobulin (669 kDa). The separation was carried out at 
4°C at a flow rate of 1.0 mL/min. The calibration curve of 
Kav versus log molecular weight was prepared using the 




for the protein, Vo = column void volume, and Vt = total 
bed volume. Size exclusion chromatography indicates rmlC 




Crystallization of RmlC was based on reported 
conditions from Kantardjieff et al, however we were unable 
to reproduce diffraction quality crystals in the reported 
condition of 0.1 M sodium citrate buffer pH 5.5, 28% 
polyethylene glycol monomethyl ether 2,000 and 0.33% 
lauryldimethylamine N-oxide (LDAO)[76]. Conditions with 
varying concentrations of each component were tested until 
diffraction quality crystals were obtained by removing all 
LDAO. The reported condition produces diffraction quality 
crystals only when all LDAO is removed, with the final 
optimized condition of 0.1 M sodium citrate buffer pH 6.1 
and 25% polyethylene glycol monomethyl ether 2,000. 
 Crystallization trials of RmlA were carried out 
through sparse-matrix commercial screens. Protein 
incubated with glucose-1-phosphate were screened against 
Wizard, PEG/ION, Index, and Crystal Screen. RmlA formed 




imidazole pH 8.0, and 200 mM CaOAc producing rods 
appearing most amenable to optimization. Repeated attempts 
at producing RmlB crystals in the presence of NAD+ 
resulted in spheroids in 30% PEG 5,000 MME, 0.2 M ammonium 
sulfate, and 0.1 M MES pH 6.5. RmlD did not yield crystals 
in the screening matrices used. 
 However, no condition was able to produce crystals of 
RmlA and RmlB which produced a solvable data set upon x-
ray diffraction trials. The resulting reflections were 
highly mosaic and unable to be processed. Initially 
suspected as a cryoprotectant issue, many cryoprotectants 
were attempted such as glycerol, PEG 400, PEG 8,000, and 
ethylene glycol. No improvements occurred regardless of 
cryoprotectant. 
 Triazinoindol-benzimidazolone co-crystallized rmlC 
crystals were soaked in mother liquor for ten minutes and 
flash frozen in liquid nitrogen. X-ray diffraction data 
was collected at our home source at Texas A&M University, 
College Station, TX. Data sets were processed using 







Evaluation of untested triazinoindol compounds 
 
 Additional compounds containing the core 
triazinoindol with substitutions in the benzimidazolone 
group were purchased from Chembridge. In addition, one 
compound containing both cores but with a different 
substitution at the R1 position was also purchased. 
Attempts at cocrystallization were made for each compound. 
The compounds were dissolved in DMSO to 100 mM and added 
to 20 mg/ml rmlC protein, diluting to 1mM. After 
incubating 1 hour on ice, the protein-compound solution 
was mixed in a 1:1 ratio with the optimized 
crystallization condition of 0.1 M sodium citrate buffer 
pH 6.1 and 25% polyethylene glycol monomethyl ether 2,000. 
The samples were spun down at 14 krpm at 4°C for 10 
minutes. Crystals formed overnight and were collected at 
our home source R-axis over 180 degrees with 1 degree 




 Initial phases were obtained by molecular replacement 




search model[78]. Each data set was refined against the 
resulting models and iterative cycles of model building 
and refinement were performed with Coot 0.8.9.1 and 





 A 40 µM stock solution of the compound was prepared 
in DMSO. 195 µL of mouse plasma and 195 µL of phosphate 
buffered saline (pH 7.4) was added to a centrifuged tube 
and incubated for 15 minutes at 37°C. The assay was 
initiated by adding 10 µL of the 40 µM stock solution to 
the plasma/PBS mixture. At times 0, 15, 30, 60, 90, 180, 
and 240 minutes a 50 µL sample was removed and added to 
100 µL of cold acetonitrile. 150 µL of acetonitrile 
containing 1 µg/mL of Warfarin internal standard was added 
and the tubes vortexed and centrifuged at 14,000 rpm for 
10 minutes. 100µL of supernatant was transferred to LC-MS 
glass vial inserts with 10 µL being used for analysis. LC-
MS was calibrated using sodium formate peaks. Extracted 
Ion Chromatogram was used to find the target and Warfarin 




for all time points. The percentage of the parent compound 
loss was calculated over time. 
 
Plasma protein binding assay 
 
 A 1 mg/ml stock solution of the compound was prepared 
in DMSO and diluted with mouse plasma to a final 
concentration of 10 µg/ml. Clozapine (high binding) and 
fluconazole (low binding) are used as experimental 
controls. The mixture was incubated at room temperature 
for 15 minutes, after which 300 µL of phosphate-buffered 
saline was added to the white wells and 100 µl of the 
plasma-compound mixture was added to the red wells of a 
Thermo Scientific Rapid Equilibrium Dialysis plate and 
sealed with clear film. The plate was incubated at 37°C 
for 5 hours at 250 rpm. 50 µL from each red and white well 
were pipetted into separate centrifuge tubes. 50 µL of 
fresh plasma was added to the buffer sample and 50 µL of 
PBS to the plasma sample. 200 µL of fresh acetonitrile 
containing 1 µg/ml Warfarin was added to each tube. 200 µL 
of freshly prepared water containing 0.1% formic acid was 
added to each tube and vortex. Tubes were centrifuged at 




transferred to LC-MS autosampler vials with a 10 µL 
injection. The LC-MS was calibrated using the sodium 
formate peaks. Using an extracted ion chromatogram, the 






 ×  100 
 
Where, Pl = Ratio of mass intensities of the compound 
and Warfarin in the plasma compartment 
Bu = Ratio of mass intensities of the compound 
and Warfarin in the buffer compartment 
% 𝑢𝑛𝑏𝑜𝑢𝑛𝑑 = 100 − % 𝐵𝑜𝑢𝑛𝑑 
 
Internal standards clozapine and fluconazole should have 
approximately 94% and 9% bound, respectively. 
 
Kinetic solubility assay 
 
 A 5 mM stock solution of the compound was prepared in 
DMSO. 10 µL of the stock solution was added to 490 µL of 
filtered 0.1 M sodium phosphate buffer, pH 7.4, into a 




added to each well and let spin for 24 hours at room 
temperature at approximately 4 rpm. After 24 hours, the 
plate was centrifuged at 1,000 x G for 1 minute. 20 µL of 
supernatant was added to 180 µL of phosphate buffer in an 
LC-MS autosampler vial. To prepare for single point 
calibration, 10 µL of the stock solution was added to 490 
µL of methanol. From this solution, 20 µL were removed and 
added to 180 µL of methanol in an LC-MS autosampler vial. 
The LC-MS was calibrated using the sodium formate peaks. 
After running samples and standards, the mass area of the 
compound was determined in both buffer and methanol 
samples using an extracted ion chromatogram. Assuming the 
mass area of the methanol sample to be 100%, the percent 
solubility was calculated using the below equation. 
 
𝐶𝑜𝑚𝑝𝑜𝑢𝑛𝑑 𝑀𝑎𝑠𝑠 𝐴𝑟𝑒𝑎 (𝐵𝑢𝑓𝑓𝑒𝑟)
𝐶𝑜𝑚𝑝𝑜𝑢𝑛𝑑 𝑀𝑎𝑠𝑠 𝐴𝑟𝑒𝑎 (𝑀𝑒𝑡ℎ𝑎𝑛𝑜𝑙)
× 100 =  𝑠𝑜𝑙𝑢𝑏𝑖𝑙𝑖𝑡𝑦 (𝑢𝑀) 
 
Mycobacterium tuberculosis whole cell assays 
 
 Analogs of the reported compounds were tested against 
MC27000 Mycobacterium tuberculosis. In addition, compounds 
reported for rmlB and rmlD, and new analogs, but without 




cells were grown at 37°C in 7H9 media containing 0.5% 
dextrose, 0.08% sodium chloride, 0.05% tyloxapol, 0.25 
µg/ml malachite green, and 50 µg/ml pantothenate. An 
aliquot of cells was then diluted in 40 ml of the same 
media to an OD600 of 0.05. 200 µL of cells were added to 
sterile 96 well plates. Compounds dissolved in DMSO were 
added in a gradient to cells, with rifampin serving as a 
negative control and DMSO serving as a positive control. 
After seven days, 4ul/well of 0.2mg/ml Resazurin is added. 
Following an additional 24 hours of incubation, 
fluorescence values are determined on a Polarstar Omega 
plate reader at excitation 544 nm and emission 590 nm. 
Cell viability is determined as a percentage of the 
positive control. 
 
Human dermal fibroblast cytotoxicity assay 
 
 Human dermal fibroblasts (HDF) at a density of 
64,000/mL were plated in 384-well plates at 40µL/well with 
a final DMSO concentration of 0.25% and allowed to 
incubate for 4 hours. Test compounds were added to the 
wells containing cells at appropriate dilution 




was added to the wells and further incubated for an 
additional 24 hours. The plate was then read using 
fluorescence intensity (excitation 530 nm; emission 590 
nm). Results were graphed using Graphpad Prism version 
8.0.0. 
 
Bioavailability measurements in a mouse model 
 
 Six-week old female ND4 Swiss Webster mice (~20 g 
each) (Envigo, Indianapolis, IN) were used for 
pharmacokinetic studies. For oral administration compounds 
were formulated in 5% DMSO, 95% canola oil and 
administered as a single 100 µL oral gavage at 10 mg·kg-1. 
For intravenous administration, compounds were formulated 
in 20% Captisol® (CyDex Pharmaceutical, INC) aqueous 
solution and administered as a single 100 µL retro orbital 
bolus injection at 3 mg·kg-1. Mice were anesthetized using 
isoflurane and 50 µL of blood was collected at 0, 0.25, 
0.5, 1, 2, and 4 hours post compound administration. Each 
mouse received two survival bleeds for total collected 
volume of 100 µL or <10% total animal blood volume in 
accordance with animal welfare regulations[81]. Terminal 




administration. Survival bleeds were drawn from the facial 
vein and terminal bleeds via cardiac puncture following 
CO2 asphyxiation[81]. Three mice were used per time point.   
Blood samples were centrifuged (3,000 x g, 15 min) 
for plasma separation. 10 µL aliquots of plasma were 
extracted with two 500 µL equivalents of methanol 
containing 0.1% formic acid to ensure maximum recovery of 
compound from plasma. The supernatant was collected from 
precipitated protein pellet following centrifugation 
(3,000 x g, 5 min) and evaporated to dryness using a 
temperature-controlled Eppendorf Vacufuge at 30°C for 4 
hours. The dry samples were reconstituted with 100 µL of 
methanol (1:10 original analyte dilution factor) spiked 
with 250 ng·mL-1 verapamil (Sigma-Aldrich) as an internal 
standard and subjected to LC-MS analysis on a Bruker 
Daltronics micrOTOF-Q II mass spectrometer coupled with an 
Agilent 1200 Infinity series HPLC with temperature 
controlled autosampler (24°C) and photodiode array 
detector. Standard solutions of compound ranging from 1000 
ng·mL-1 to 7.8125 ng·mL-1 spiked into mouse control plasma 
was also analyzed to generate a calibration curve 
corrected for matrix effects. A linear regression 




samples. The LOD of the LC-MS method was approximately 2 
ng·mL-1. A 4.6 X 100 mm Kinetex® 2.6 µm EVO C18 100 Å 
column at a flow rate of 0.5 mL·min-1 was used in the 
analysis. The mobile phase consisted of water containing 
0.1% formic acid as solvent A and acetonitrile with 0.1% 
formic acid as solvent B. The gradient conditions were 
maintained as follows: 90% A, 10% B to 100% B in 8 min; 
100% held for 4 min as a washing step; 100% B back to 90% 
A in 2 min; 90% A, 10% B held for 3 min to reset and 
equilibrate the column.  
Each analytical run was automatically calibrated 
using a secondary line injection of 10 µL sodium acetate 
external standard at 13 min. The injection volume of the 
analyte was 10 µL and MS was operated in positive mode 
with electrospray ionization at source. Mass spectra were 
monitored in a range of 50 to 1000 m/z. Data was processed 
using DataAnalysis 4.1 and QuantAnalysis (Bruker 











Triazinoindol-benzimidazolone analog evaluation 
 
In an attempt to build upon Sivendran et al, five 
additional compounds were purchased from Chembridge to 
explore substitutions of the benzimidazole moiety as well 
as a substitution of the R1 position[1]. As Sivendran had 
already demonstrated that groups added at R2 resulted in a 
dramatic loss of activity, we did not explore R2 
substitutions. Compound 7049574 is identical to 6904191 
but with a longer linker on the phenyl group. The other 
four compounds were chosen to further probe the active 
site as well as substitute the benzimidazole moiety with 
one that would increase the polar surface area without 
sacrificing inhibition. An increased polar surface area is 
associated with improved oral bioavailability. The ClogP 
of the triazinoindol-benzimidazolones was often in 
conflict with Lipinski’s rules or borderline. Our testing 
of the kinetic solubility of the compounds from Sivendran 
et al confirms this, suggesting they would likely have 




None of the new compounds were amenable to 
cocrystallization or soaking. After solving the structures 
of known potent triazinoindol-benzimidazolones, it became 
clear that the benzimidazole moiety is essential for 
activity. The benzimidazole moiety mimics the 
deoxyriboside residue of the substrate and forms a strong 
pi-pi stacking interaction with TYR138. Assuming a 
maintenance of a similar mode of binding, the 
benzimidazole must be replaced with a residue also capable 
of pi-pi stacking with TYR138. 
Compound 5225634 is lacking the benzimidazole 
entirely without a substitution to determine the role the 
triazinoindol plays in binding. We did not observe density 
in the active site, suggesting that the benzimidazolone 
group may play a more pivotal role and that substitutions 
of the triazinoindole group may instead be the more 










 rmlC compounds 6665037 and 7093044 were tested for 
kinetic solubility. As predicted based on calculated log P 
values of 4.12 for 6665037 and 5.18 for 7093044, the 
compounds exhibited very poor solubility. 7093044 was 
completely insoluble and 6665037 was only soluble to 2 µM. 
However, reported rmlD inhibitor 5104346 exhibited a 
considerably higher kinetic solubility, up to 98 µM. 
 
 












Figure 7: RmlD inhibitor compounds 
Compounds from virtual screening reported in 
Wang[2] and our analogs chosen based on active 
site modeling. 5137172 and 5104346 from Wang have 




























Figure 8: Triazinoindol-benzimidazolone scaffold 
and IC50’s 
Triazinoindol-benzimidazolone scaffold with 
associated R-groups and IC50 values alongside Mtb 
MIC values[1] 
The core molecule picture above was tested with 
substitutions at various positions, denoted in the 
chart. IC50 values were calculated from enzyme 
assays and the MIC values were determined from 
testing on M. tuberculosis cells. 
Reproduced with permission from publisher 







7077074 CH2=CH–CH2 H 3 0.12 13
6892686 CH3–CH2 H 3 0.2 19
6665037 CH3– H 3 0.5 9
7093044 CH3–CH2–CH2 H 3 1.25 9
6904191 H 3 2.9 >50
6922675 H H 3 3.3 ND




Plasma Protein Binding 
 Plasma protein binding results of two compounds thus 
far suggest this series, as is, has a very high percentage 
bound. Without further study, it is difficult to suggest 
whether the concentration of drug would be sufficient to 
kill M. tuberculosis in vivo. 6665037, with a methyl 
substitution at R1, displays a slightly lower plasma 
















Compound % bound St. Dev.
6665037 97% 0.004
7093044 >99% 0.001
Table 1: Plasma protein binding results 
Results were obtained for two of the 
triazinoindol-benzimidazolones. Both compounds 
show considerable plasma protein binding, which 
may affect the concentration of drug being high 




Crystal structures of triazinoindol-benzimidazolones 
 
 Multiple RmlC-inhibitor complex structures were 
solved to examine structural features and interactions of 
the inhibitors with the active site. Crystal structures 
were obtained of 7077074, 6892686, 6665037, 6922675, and 
7093044. Cocrystallization proved sufficient to visualize 
bound inhibitors in the active site. 
 Upon observing the completed structures it became 
apparent why 6904191, with its methylphenyl substitution 
was R1, was not amenable to a crystal structure despite 
having an IC50 only slightly more than the others. 6904191 
only shows weak electron density. The symmetry mate’s 
His19 R-group does not allow for such a large hydrophobic 
residue to bind well in a crystal structure. This would 
not occur in solution, hence why a relatively low IC50 of 

















Figure 9: 5 RmlC inhibitor structures overlayed  
Only 6922675 (light green) shows a notable but minor 
deviation. The lack of a group at R1 disallows a 
hydrophobic interaction between the benzene ring of the 
benzimidazole moiety and small carbon chains found in 
other inhibitors.  
Tyr138 and Arg59 are notably disturbed, with the 
guanidino group of Arg59 shifted 1.7 Å and the 
hydroxybenzene of Tyr138 shifted 1.0 Å. This shift is 
very unfavorable, resulting in an IC50 ranging from 3 to 






In 2010 Sivendran et al published a report on the 
triazinoindol-benzimidazolone class of compounds 
discovered via high throughput screening[1]. The study 
included multiple analogs picked from the library and 
evaluated enzymatically and docked. To date, no structures 
of rmlC with any triazinoindol-benzimidazolone, or any 
inhibitor, have been published. Presenting an opportunity 
for further evaluation with experimental data, the 
structures of multiple triazinoindol-benzimidazolones were 
solved in complex with Mtb rmlC. The structures were also 
compared to the published docking models. An explanation 
for why specific R-groups provided greater enzymatic 
inhibition was forthcoming in our analysis. 
Two docking models were presented in Sivendran, with 
one significantly more in agreement with our structure. 
However, using the solved pathway product structure as the 
docking model resulted a model with the triazinoindol-
benzimidazolone positioned akin to dTDP-rhamnose in the 
solved structure. The benzimidazolone moiety still forms 




rest of the compound is positioned deep within the active 
site. 
 
As shown in the above figure, the triazinoindol-
benzimidazoles make no contact with any of the catalytic 
residues. This may explain why the compound series is so 
potent despite making few strong bonds. By sitting at the 
surface of the active site rather than inside the active 
site, the substrate and the triazinoindol-benzimidazolones 
compete for few interactions. The triazinoindol-
Figure 10: 7093044 structure 
Overlay of 7093044 structure (blue) with dTDP-rhamnose 
structure (green). The rhamnose moiety of dTDP-rhamnose 
resides deep within the active site in contact with the 
catalytic residues Tyr132, Lys72, and His62. Active site 
residues are largely unchanged, save for a 2.5 Å movement of 




benzimidazolones effectively serve as a lid over the 
active site, preventing substrate access. 
Only one substitution at R2 was assayed. In 
Sivendran, it was hypothesized based on the docking model 
that the addition of a methyl group at the R2 position 
will cause steric clash with His119 and Phe121. Upon 
solving the crystal structure, it became apparent this was 
not the case. The addition of a methyl at R2 would put it 
within close proximity to the guanidino group of Arg59. 
This decrease in solvation of Arg59 is energetically 
unfavorable and also introduces an interaction between the 
hydrophobic methyl group and the hydrophilic guanidino 
group. In addition, the methyl group would push Arg59 











The substitutions at R1 play a significant role in 
binding. The length and type of carbon chain affects the 
hydrophobic interaction the triazinoindol-benzimidazolones 
have with themselves. Commonly referred to as a 
hydrophobic interaction, it could be argued that 
hydrophobic exclusion is a more appropriate term. This 
refers to the observed tendency of nonpolar substances to 
aggregate in an aqueous solution and exclude water 
molecules[83]. 
Figure 11: 7093044 structure showing effects of 
R2 substitution 
Structure of 3044, with emphasis on Arg59 
(right), suggesting a major perturbation would 




Research into hydrophobic interactions have a well-
studied but storied history[84]. The hydrophobic 
interaction is responsible for the low solubility of 
hydrophobic molecules in water. This has a central role 
both micelle formation and the structure of proteins[85, 
86]. The strong tendency of hydrophobic molecules to 
aggregate in a polar solution was such that there was once 
suspected to be a “hydrophobic bond” associated with 
it[85, 87]. It is now recognized that the hydrophobic 
interaction involves the configurational rearrangement of 
water molecules as two hydrophobic species come together 
in solution[88-91]. The hydrophobic interaction has an 
effect over a much wider area than a typical covalent 
bond. Measurements show that the hydrophobic interaction 
has roughly the same range as the van der Waals-dispersion 
force but is about an order of magnitude stronger. The 
strength of the hydrophobic interaction decays 
exponentially over the range of 0–10 nm[92]. 
The most potent of the triazinoindol-benzimidazolones 
are ones with no substitutions at R2 and small, 
hydrophobic carbon chains at R2. The hydrophobic effect 
and the shape of the hydrophobic regions of the inhibitors 




hydrogen bonding interactions between the O01 oxygen of 
7093044 and the ND2 and NE2 nitrogens of Asn49 and Gln47, 
respectively. 
Noting the essentiality of the pi-pi stacking between 
the benzimidazolone group and Tyr138, it is reasonable to 
suggest a simple point mutation would render these 
compounds ineffective. However, Tyr138 also forms this 
same interaction with the substrate’s thymidine group. 
While a mutation to phenylalanine would still allow the 
substrate to position itself, the inhibitors would also 
still have a benzene ring to interact with. 
The lack of observed toxicity with any compounds in 
the series suggest the triazinoindol-benzimidazolones may 
a starting point as a scaffold, with modifications in the 
triazinoindol group, or possibly a different group 
altogether, to increase kinetic solubility[93]. As of now, 
it appears to largely serve as a placeholder, only making 





Figure 12: Docking structure of RmlC-6892686[1] 
The benzimidazolone pi-pi stacking with Tyr138 is in 
agreement with our crystal structures, while the 
triazinoindol group is found at the mouth of the active 
site rather than in contact with active site catalytic 
residues deeper within 
Reproduced with permission from publisher Elsevier, 








Figure 13: RmlC-6892686 structure 
The pi-pi stacking interaction between Tyr138 is consistent 
with the docking model. However, the benzimidazolone 
orientation is reversed and the triazinoindol is on the 










Figure 14: RmlC-7093044 electrostatic map 
Electrostatic potential surface map of rmlC with 7093044 
bound. There are considerable empty regions available 
for modifications to the compound series. 
In particular, the addition of a hydroxyl group to the 
end of the propyl moiety of 7093044 would likely 
hydrogen bond with the Arg170’s positively charged 
guanidino group. Currently, the propyl group makes no 
bonds and contributes to the high ClogP. The ClogP 











































Figure 15: Cytotoxicity data of inhibitors 
No compounds show any significant toxicity up to 













Figure 16: Ligplot diagram of 7093044 interactions 
Two hydrogen bonding interactions between the O01 
oxygen of 7093044 and the ND2 and NE2 nitrogens of 
Asn49 and Gln47, respectively. 
The predominant hydrophobic interaction is between 





STRUCTURAL AND FUNCTIONAL INSIGHTS INTO INHIBITION OF UDP-





 Pseudomonas aeruginosa is the causative agent for an 
estimated 51,000 infections in the United States each 
year, including 400 deaths. The bacterium is inherently 
resistant to most clinical antibiotics, with some 
exceptions including fluoroquinolones and specific β-
lactams. To date, there has been only a single PDB 
deposition of P. aeruginosa MurA with no associated 
publication or analysis. We present a detailed analysis of 
P. aeruginosa MurA with various inhibitors, substrate, and 
product. To produce this analysis, we soaked or co-
crystallized MurA with these compounds to capture them in 
the active site. While the MurA enzymes exhibit very high 
homology across species, slight variations between 
published structures and P. aeruginosa are observed. The 
inhibitor structures successfully obtained were of 




We also evaluate published enzymatic inhibitors for their 
whole cell activity. The only recently published enzymatic 
inhibitor that exhibited whole cell activity was 
carbidopa, a dopamine decarboxylase inhibitor administered 
to people with Parkinson's disease in order to inhibit 
peripheral metabolism of levodopa. Additional dopamine 
decarboxylase inhibitors, benserazide difluromethyldopa, 
and α-methyldopa, are available and may provide a starting 





The antibiotic fosfomycin is able to treat non-resistant 
strains of P. aeruginosa, however, increasing pressure 
from resistance mechanisms including FosA, multi-drug 
efflux pumps, and C115 mutations have accelerated the need 
to have alternative treatments. Given the covalent nature 
of fosfomycin, a mutation in C115 results in a near 
complete resistance to the drug’s effects. While certain 
β-lactams remain efficacious against more standard 
strains, the increasing spread of resistance genes in P. 




suggest that reliance on β-lactams should be a resort of 
decreasing reliance as the resistance rates outpace the 
creation of newer and more effective drugs[94-96]. 
 The inhibitor class commonly associated with MurA is 
one of covalent modification. Many attempts at creating 
analogs of fosfomycin have been attempted but have not 
been effective enough for continued consideration[97]. 
Issues range from lack of whole cell efficacy to toxicity 
from nonspecific cysteine modification. Fosfomycin is 
remarkable for its ability to only modify the active site 
cysteine in MurA, without peripheral and nonspecific side 
effects[98]. It is absorbed and excreted in the urine 
unchanged[99]. However, the reliance on covalent 
modification has resulted in some strains of P. aeruginosa 
having a mutation from cysteine to aspartate, resulting in 
fosfomycin bactericidal activity being abolished[100]. 
Indeed, the Mycobacterium tuberculosis MurA has long been 
known to be immune to the effects of fosfomycin and this 
comes from the wild type MurA containing aspartate instead 
of cysteine[101]. 
 This reliance on covalent modification begs a 
question. Why are there no approved drugs that utilize a 




purified enzyme, depending on the bacterial species from 
which it is derived, almost always contains the substrate 
UDP N-acetylglucosamine or the MurB product, UDP MurNac, 
bound to the active site[102]. Attempts to remove it with 
repeated washings or high ionic strength conditions proved 
futile. The large substrate (607.35 g·mol−1) contains many 
interactions with the active site and the mechanism by 
which the enzyme operates necessitates the binding of UDP 
N-acetylglucosamine first[103]. The tight binding could be 
considered to be a defining reason why inhibition by a 
different mode of action has had limited success. 
 If efforts are steered away from covalent 
modification and competitive inhibition via the region of 
the active containing UDP N-acetylglucosamine, that would 
present the region where phosphoenolpyruvate (PEP) reacts 
with UDP-N-acetylglucosamine as a potential target. This 
region has a degree of solvent exposure and could 
theoretically provide a means to be a site of inhibition 
against phosphoenolpyruvate. 
MurA presents itself as an excellent candidate for 
antibiotic design, as it is an essential, highly conserved 
enzyme across Gram-negative and Gram-positive bacteria and 




exist very successful cases of targeting enzymes found in 
both humans and bacteria, the task of designing a new drug 
is theoretically less burdensome without concern for cross 
reactivity with the human homolog. For instance, the 
macrolides are a common antibiotic used to treat bacterial 
infections. They have long been known to target the 
bacterial ribosome. However, certain macrolides such as 
kanamycin have been supplanted by alternatives because of 
well-documented side effects, including ototoxicity[104, 
105]. Even the to this day commonly prescribed 
azithromycin has a documented history of causing permanent 
hearing loss[106].  It has been shown that macrolides have 
varying degrees of inhibition against the human 
ribosome[107]. This cross reactivity is why certain 
macrolides have either never made it to FDA approval or 
have been largely shelved, although examples such as 
azithromycin have been weighed and found that the risk 
potential is exceeded by its therapeutic value. 
By creating a comprehensive structure-based analysis 
of P. aeruginosa MurA, we elucidate both the similarities 
and differences among these bacterial enzymes. 
Furthermore, we offer a structural explanation for the 




versus known MurA-fosfomycin structures solved in other 
bacteria. The P. aeruginosa MurA is, to date, lacking any 
published structural analysis and this body of work 
addresses this missing component in the MurA literature. 
 
MATERIALS AND METHODS 
 
Cloning, expression, and purification 
 
Wild-type MurA was amplified from P. aeruginosa PAO1 
genomic DNA using Phusion polymerase from New England 
Biolabs and inserted into the NdeI and HindIII sites in 
pET28b. Forward and reverse primers were TTTTTTCATATG 
GATAAACTGATTATTACCGGCGGTAACC and 
TTTTTTAAGCTTCTAGCCCGGTACGCG, respectively. These resulted 
in an N-terminal hexahistine tag. Sequences were confirmed 
by Eton Bioscience. Plasmids were transformed into the 
Invitrogen E. coli BL21 (DE3) strain. To produce the 
protein, the bacterial cultures were grown at 37°C at 180 
rpm in LB medium until an OD600 of 1.0 was reached. 
Following cooling down to 20°C for 60 minutes, the 
cultures were induced with 1.0 mM isopropyl-β-D-




20°C, harvested and resuspended in lysis buffer (10% 
glycerol, 100 mM NaCl, 25 mM (NH₄)₂SO₄, 10 mM imidazole, 
20mM HEPES pH 7.4, and 0.5 mM TCEP). Cells were disrupted 
via French Press at 20,000 PSI and the insoluble cellular 
material was removed by centrifugation at 13,000 rcf for 1 
hour. MurA purified using Ni-NTA affinity chromatography 
in a gravity column through multiple volumes of wash lysis 
buffer until eluent samples no longer produced a visible 
color change with Bradford protein quantification reagent, 
indicating washing was complete. Proteins were eluted with 
elution buffer (5% glycerol, 50 mM NaCl, 25 mM (NH₄)₂SO₄, 
200mM imidazole, 10mM HEPES pH 7.4, and 0.5 mM TCEP) until 
eluent samples no longer produced a visible color change 
with Bradford protein quantification reagent, indicating 
elution was complete. Samples were then concentrated using 
Millipore Amicon Ultra-15 centrifugal filter units and 
injected onto a GE S200 size exclusion chromatography 
column. Peaks corresponding to the target protein were 
collected and concentrated to 12 mg/mL. Individual 








Size exclusion chromatography 
 
The molecular weight of MurA in solution was 
determined by size-exclusion chromatography using a 
Superdex 200 GE Healthcare 16/60 column. The column was 
calibrated with aprotinin (6.5 kDa), carbonic anhydrase 
(29 kDa), conalbumin (75 kDa), catalase (232 kDa), and 
thyroglobulin (669 kDa). The separation was carried out at 
4°C at a flow rate of 1.0 mL/min. The calibration curve of 
Kav versus log molecular weight was prepared using the 
equation Kav= (Ve-Vo/)/(Vt-Vo,), where Ve = elution volume 
for the protein, Vo = column void volume, and Vt = total 
bed volume. Size exclusion chromatography indicates MurA 




 MurA was screened against crystallization sparse 
matrix screens Wizard, Index, Crystal Screen, and PEG/ION. 
Two forms of the protein, substrate-bound and product, 
were screened in a sitting drop vapor diffusion method at 




condition for each was found after 48 hours. The 
substrate-bound condition is 12% MPD, 16% PEG 2000, and 
10% Tacsimate pH 5.4. The product-bound condition is 24% 
PEG 2000 and 10% Tacsimate pH 5.8. Following initial hits, 
hanging drops were set up at a ratio of 3:3 µL and 
equilibrated against 0.5 ml of mother liquor to produce 
larger crystals. Crystals were transferred to a 
stabilization solution containing 30% glycerol in mother 
liquor and allowed to equilibrate for 10 minutes. Crystals 
were flash frozen in liquid nitrogen. Data Collection and 
Processing. X-ray diffraction data was collected on 
beamlines 19ID and 23ID at The Advanced Photon Source, 
Argonne National Laboratory, Argonne, IL. Data sets were 
reduced using HKL2000. Data was collected at a temperature 




 An alignment of 10 amino acid sequences from 
deposited MurA structures in the Protein Data bank was 
performed using Jalview for visualization and Clustal for 
aligning. Sequence identity was also highlighted to show 




taxonomic classifications as high as phylum. The active 





Whole cell inhibition 
 
 6 compounds were evaluated for their ability to 
inhibit or kill Pseudomonas aeruginosa strain PAO1. Only 
carbidopa showed any significant decrease in viability. P. 
aeruginosa is known to have multiple drug efflux pumps, 
giving it a wide resistance to small molecule inhibitors. 
These results are not entirely unexpected and reinforce 
the difficulty in developing inhibitors that are active 
against both the enzyme and the cell itself. 
 As we were unable to obtain a structure with 
carbidopa bound despite some enzymatic inhibition, we 
cannot rule out off target activity. Carbidopa was 
designed as a treatment for Parkinson’s disease and not 
intended to treat bacterial infections. However, 
modifications to carbidopa as a lead molecule towards 



































Figure 17: PAO1 whole cell assay 
Effects of MurA enzymatic inhibitors against PAO1 
Pseudomonas auruginosa. 100µM ciprofloxacin was used 





Crystallization and Structures 
 
     MurA proved amenable to crystallization, 
cocrystallization, and soaking. All crystals diffracted to 
~2 Å or better, with low mosaicity. 
     Structures were solved of MurA with the co-purified 
substrate UDP-NAG, product UDP-NAG-EP, UDP-NAG and 







Figure 18: MurA-product structure 
Structure of product UDP-NAG-EP within the 
active site of MurA. Note the active site lid 
in the foreground in front of UDP-NAG-EP. 
This loop opens and closes to allow substrate 















(continued) Figure 19: Sequence alignment of MurA from 
the PDB 
Alignment of ten MurA amino acid sequences from 
structures deposited in the Protein Data Bank. Active 
site cysteine boxed in red. Despite members representing 
different phyla, the high degree of conservation 
showcases the ancient nature of peptidoglycan 














Figure 20: Overlay of pathogenic MurA structures 
Overlay of 5 MurA structures from pathogenic species 
with the substrate UDP-NAG bound. The active site 
residues bonding with UDP-NAG are highly conserved, with 
the catalytic residues conserved entirely. The active 
site lid containing the active site cysteine is pictured 







     MurA has been a drug target for decades. However, no 
development of antibiotics has led to a treatment regimen 
save for the original and lone fosfomycin. Given the 
extensive and successful research into the downstream 
peptidoglycan biosynthetic enzymes, it is surprising that 
fosfomycin remains the sole source of antibiotics for the 
Mur pathway with no analogs. Dozens of antibiotics exist 
for targeting the transpeptidases and advancements 
continue to be made. However, β-lactamases have evolved 
and their genes spread among pathogenic species to the 
point that expecting them to continue to comprise over 
half of prescribed antibiotics presents a risk. The 
discovery of NDM-1 and tracking its spread among species 
elicited a panic throughout the medical and scientific 
professions, with concerns that if it became widely 
distributed it could have a major impact on treating 
infections with β-lactams often being the first prescribed 
antibiotic. 
     MurA presents itself as an excellent candidate for 
antibiotic design, as it is an essential, highly conserved 




there is no known human counterpart. While certainly there 
exist very successful cases of targeting enzymes found in 
both humans and bacteria, the task of designing a new drug 
is theoretically less burdensome if a balance between 
minimal human interference versus maximal bacterial 
interference need not be considered. 
     The P. aeruginosa MurA structure is highly similar in 
its overall fold to other MurA structures. This is 
expected given both the ubiquitous (in bacteria) and 
essential nature of MurA, lending to the high sequence 
conservation. Sequence similarity is often greater than 
70%. As with other MurA structures, it exhibits the 
standard two globular domains connected by a double 
stranded linker. A loop containing C115 and other active 
site residues closes over the substrate UDP-GlcNAc upon 
binding. The domains are comprised of three parallel 
helices surrounded by three additional helices and three 
beta sheets. 
     Of the six compounds tested against cells, only 
carbidopa showed any efficacy and even then, only at 
concentration approaching 100 µM. Other compounds have 




tulipalins, but with the critical problem of off target 
activity, leading to cytotoxicity. 
     One structure to note is the fosfomycin-product 
structure of MurA. This was unexpected because it was 
predicted that fosfomycin would not covalently bind to 
C115 if the product was bound. Indeed, no other MurA-
fosfomycin-product structures have been published. While 
there are no notable structural differences between the 
fosfomycin-product and fosfomycin-substrate structures, 
this new structure shows that fosfomycin activity is not 
limited to only the substrate-bound MurA. It would be 
interesting to test other MurA’s from published structures 
in other species to attempt to produce a MurA-fosfomycin-
product structure. It seems unlikely that P. aeruginosa 



















Figure 21: PEP hole in MurA-product structure 
MurA product structure, Exposed region of 





CONCLUSION AND FUTURE DIRECTIONS 
 
The triazinoindol-benzimidazolone compounds show both 
high enzymatic potency and modestly low M. tuberculosis 
MIC’s. The most kinetically soluble, 6665037, displays a 
high plasma protein binding, however, an animal model is 
needed to determine if serum levels reach a high enough 
concentration to prove effective against an infection. The 
lack of observed toxicity up to 100 µM in human dermal 
fibroblasts suggests a preliminary safety of the 
compounds. 
Depending on the results of an animal model for serum 
concentration, modifications to the triazinoindol group 
would be in order. The original R2 substitutions only 
tested hydrophobic groups. With the crystal structures in 
hand, it is apparent than even a simple hydroxyl at R2 
would both improve solubility and be able to hydrogen bond 
with Arg59. As the entire series is currently very 
hydrophobic, having the ClogP more in line with current 
drugs would likely increase their value as potential 
drugs. 6665037 has a ClogP of 4.12, which does conform to 




of ClogP values of current drugs. The bulk of which range 
from 0.5 to 4.0. Adding a hydroxyl at R2 would lower the 
ClogP to 3.84, putting the compounds closer in line to the 
average. 
Regardless of enzymatic or whole cell potency, a 
serum concentration animal model must be conducted to 
ensure either the current compounds or post-modification 
reach a threshold capable of killing M. tuberculosis. This 
will likely be an iterative process, of determining the 
murine serum levels, modifications if they are not 
sufficient, retesting enzymatic and whole cell potency, 
retesting cytotoxicity, and retesting in an animal model. 
It would not be unexpected if the final molecule looked 
markedly different than the starting scaffold. 
The issue of patentability is also one to consider. 
As this compound series has been published and not 
patented, by virtue of the public announcement combined 
with a designated usage, it is unlikely the triazinoindol-
benzimidazoles would be patentable as an antibiotic. While 
patent law is outside the scope of this body of work, a 
significant modification or outright replacement of the 




and a compound worth being investigated as a potential M. 
tuberculosis antibiotic. 
Covalent modification of the active site cysteine of 
MurA has long been the direction of research relating to 
antibiotic development utilizing MurA as the enzyme 
target. This is understandable, given the success of 
fosfomycin. However, after decades of research there is 
not a single commercial analog of fosfomycin, or any other 
FDA approved covalent modifier. This is in contract to 
other classes of antibiotics. Beta-lactams contain well in 
excess of 50 examples that, while many are rarely or not 
used at all today, have been used to treat infections. The 
macrolides contain over 20 examples. 
This is not to suggest that it is not feasible to 
develop a new commercial covalent modifier. However, with 
the absolute requirement for the presence of the active 
site cysteine and the lack of toxicity even at gram-sized 
doses of fosfomycin, fosfomycin either works well or 
doesn’t work at all. A simple, and not uncommon, cysteine 
mutation protects against fosfomycin with a minimal 
fitness cost. Enzymes, such as FosA, capable of 
deactivating fosfomycin can be overcome simply by 




pressing need for a fosfomycin “upgrade”. There have 
certainly been multitudinous examples of covalent 
modifiers discovered and analyzed. 
Because of this, a non-covalent inhibitor against 
MurA would be ideal to supplement fosfomycin. As has been 
laid out, MurA has very high sequence conservation against 
taxonomically broad species. A non-covalent inhibitor 
would likely have some degree of activity across 
pathogenic and non-pathogenic species. Not relying on the 
active site cysteine would make a mutational adaptation 
less damaging to the drug’s efficacy. 
There have been a small number of non-covalent 
inhibitors published, however, none of them are potent 
enough to be considered, as they currently are, to be 
worth further evaluation[108]. Medicinal chemistry would 
need to be performed to modify the compounds to first 
improve their enzymatic inhibition. 
As MurA has been heavily researched and many 
libraries screened, it may be a more viable option to 
evaluate non-covalent inhibitors published and use them as 
a starting point for modification. That said, screening 
has recently resulted in a new inhibitor scaffold from 




inhibit MurA and a D-cycloserine mimic forms the core of 
these new molecules. While the mode of inhibition has not 
yet been published, if these prove to be non-covalent 
modifiers they could steer MurA drug research into a new 
direction. One of the compounds is enzymatically potent 
enough to warrant further investigation as to its whole 
cell potency. If it does not rely on an active site 
cysteine, it may also prove efficacious against M. 
tuberculosis, whose wild-type contains an aspartate rather 
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